Cancer and a host of other diseases manifest on a molecular level through specific biomarkers, including proteins, nucleic acids such as DNA or RNA, and various other molecular entities. The challenge with these biomarkers lies in their infinitesimal concentrations during the disease’s nascent phase, often evading detection by existing diagnostic tools. Addressing this, the newly developed sensor harnesses a multi-disciplinary approach merging nanotechnology, gene editing, and nonlinear optics to amplify detection capabilities without relying on molecular amplification methods traditionally used in biomarker assays.

At the heart of this sensor is the phenomenon known as second harmonic generation (SHG), a nonlinear optical process wherein incident photons interacting with certain materials are effectively converted into photons of twice the energy — or half the wavelength. The sensor employs molybdenum disulfide (MoS₂), a two-dimensional semiconductor distinguished by its robust SHG response. By leveraging the MoS₂’s properties, the device creates a platform where subtle biochemical interactions translate directly into measurable optical signals, circumventing common issues with background noise that plague many light-based assays.

To precisely modulate the interaction distance essential for enhancing SHG signals, the team implemented DNA tetrahedrons as nanoscopic scaffolds. These tetrahedral structures are meticulously self-assembled from DNA strands, forming rigid, pyramid-like shapes with nanometer precision. Quantum dots, semiconductor nanoparticles renowned for their size-tunable optical characteristics, were tethered to these DNA frameworks. This arrangement enables fine control over the spatial orientation and proximity of quantum dots relative to the MoS₂ surface, thereby dramatically boosting the local electromagnetic field and, consequently, the SHG intensity.

The sensor’s biomarker specificity and detection mechanism owe much to the integration of CRISPR-Cas12a, a precise gene-editing protein programmed to identify target nucleic acid sequences indicative of disease biomarkers. Upon recognizing its target, Cas12a activates collateral cleavage activity, slicing the DNA strands anchoring the quantum dots. This cleavage disrupts the engineered nanostructure, precipitating a measurable decrease in SHG signal. The direct correlation between the presence of the biomarker and SHG signal modulation endows the sensor with remarkable sensitivity and specificity, enabling detection without the need for traditional amplification methods such as PCR.

This amplification-free detection is a profound leap forward, as conventional biomarker assays often entail time-consuming and costly amplification cycles to elevate the signal beyond detectable thresholds. By contrast, the current technology’s design — combining optical nonlinearity for noise suppression, nanometer-scale engineering for signal enhancement, and molecular precision via CRISPR — fosters rapid and accurate biomarker quantification directly from clinical samples. Such efficiency is poised to redefine the landscape of molecular diagnostics.

In practical application, the team focused on miR-21, a microRNA implicated as a lung cancer biomarker. Initial tests in buffer solutions established baseline sensitivity, followed by validation within human serum extracted from lung cancer patients. The sensor demonstrated exceptional performance, effectively distinguishing the target microRNA from a milieu of structurally similar RNA molecules present in serum, underscoring both its specificity and robustness. This real-world applicability suggests a viable path toward clinical translation.

Beyond lung cancer, the sensor’s modular design and programmable DNA constructs imply versatility across a plethora of diseases and biomarkers. The detection scheme could readily adapt to viruses, bacterial pathogens, and other disease-relevant molecules, unlocking potential applications in infectious disease surveillance, environmental monitoring, and neurodegenerative disease diagnostics, such as Alzheimer’s biomarkers. This universality underscores the sensor’s broad impact potential across multiple domains of healthcare and beyond.

Looking forward, the research team has ambitious plans to transform this laboratory-scale technology into a portable, user-friendly device. Miniaturizing the optical setup and integrating it into a compact form factor could enable bedside or point-of-care testing, expanding accessibility to underserved and remote locations lacking sophisticated laboratory infrastructure. Such advancements would democratize early disease detection, empowering timely interventions and personalized patient management.

The union of DNA nanotechnology, quantum dot-enhanced nonlinear optics, and CRISPR-based molecular recognition represents a triumph of interdisciplinary innovation. This synergy facilitates an elegant sensing architecture that balances speed, precision, and minimal complexity—characteristics critical for next-generation diagnostic tools. As the technology matures and moves toward commercialization, its capacity to reshape cancer diagnostics and monitoring stands to significantly impact patient outcomes and healthcare economics.

Published in the journal Optica, under the title “Sub-Attomolar-Level Biosensing of Cancer Biomarkers Using SHG Modulation in DNA Programmable Quantum Dots/MoS₂ Disordered Metasurfaces,” this research marks a seminal contribution to the field of biomedical optics. The detailed mechanisms and experimental validations outlined exemplify how fundamental physics and molecular biology can converge to create disruptive technologies in medicine.

In summary, the development of this highly sensitive SHG-based biosensor integrates the nanoprecision of DNA assembly, the optical enhancement of quantum dots, and the molecular specificity of CRISPR-Cas12a. This marriage of techniques enables the amplification-free detection of cancer biomarkers at previously unattainable sensitivity levels, bringing the prospect of rapid, accurate, and non-invasive cancer detection closer to reality. As such, it holds tremendous promise for revolutionizing how clinicians detect and monitor diseases, ultimately facilitating earlier interventions and improving survival outcomes worldwide.

Subject of Research: Cancer biomarker detection using light-based sensing technologies.

Article Title: Sub-Attomolar-Level Biosensing of Cancer Biomarkers Using SHG Modulation in DNA Programmable Quantum Dots/MoS₂ Disordered Metasurfaces

Web References:

• DOI Link
• Optica Journal Homepage

References:
B. Du, X. Tian, S. Han, Y. Liu, Z. Chen, Y. Liu, L. Li, Z. Xie, L. Gao, K. Jiang, Q. Jiang, S. Chen, H. Zhang, “Sub-Attomolar-Level Biosensing of Cancer Biomarkers Using SHG Modulation in DNA Programmable Quantum Dots/MoS₂ Disordered Metasurfaces” Optica, 13 (2025).

Image Credits: Han Zhang, Shenzhen University

Keywords: Cancer research, Quantum dots, Metasurfaces, Clinical medicine

Carbon nanotubes, particularly single-wall configurations, possess unique electrical and chemical properties that can be fine-tuned depending on their chirality—the specific way in which the graphene sheet is rolled into the tubular structure. Traditionally, the production process of these nanotubes generated a mixture of conductive and semi-conductive variants, posing a challenge for researchers aiming for specificity in application. The recent innovations from the University of Turku address this challenge head-on by introducing techniques for separating nanotubes based on their chirality. By doing so, researchers can exploit the distinct electrochemical properties that arise from even subtle differences in chirality to develop a new class of sensor materials.

This innovative technique, spearheaded by Han Li, a Collegium Researcher in materials engineering, has paved the way for a detailed understanding of how these tiny structures act in sensor technologies. Researchers successfully distinguished between carbon nanotubes that exhibit very similar chiral characteristics, shedding light on their electrochemical responses. This differentiation is crucial, as the nuances of chirality can significantly influence the efficacy of sensors. “Although the difference in the chirality of the nanotubes is very slight, their properties are very different,” notes Ju-Yeon Seo, a Doctoral Researcher involved in the study. Such insights could propel the next wave of sensor technology development, particularly in areas that demand high precision.

Central to the effectiveness of these sensors is the ability to accurately control the concentration of the nanotubes used. The study achieved this feat by fabricating sensors that consist solely of carbon nanotubes, contrasting with traditional methods where additional surfactants are often incorporated. This purity not only enhances the performance of the sensors but also allows for a more accurate comparison of each nanotube’s properties. One of the striking findings from the research is that a specific type of nanotube—designated (6.5)—was observed to possess a greater efficiency in adsorbing dopamine than another variant labeled (6.6). This differential performance underscores the importance of chirality in nanomaterial applications.

Adsorption plays a pivotal role in sensor design, especially in the context of detecting low concentrations of biomolecules. The ability of materials to bind with other atoms or molecules is critical when it comes to measuring substances present in minute quantities. In the world of biomedical sensors, where hormones like estrogen exist in levels that can be millions of times lower than glucose, the performance of sensor materials can dictate the success of clinical diagnoses and ongoing health assessments. Researchers at the University of Turku are dedicated to developing biosensors that not only meet but exceed the current standards for accuracy and sensitivity.

The innovative research findings also suggest that controlling the electrochemical properties of carbon nanotubes could lead to refinements in how we understand hormone fluctuations within the human body. As the team looks forward, computational models may be employed to optimize chirality further, tailoring the nanotube materials toward specific hormones or other biomolecules of interest. This tailored approach could transform our ability to conduct dynamic health assessments, allowing for a deeper understanding of hormonal health and overall bodily functions.

The implications of this research are broad, reaching into the realm of continuous health monitoring—a concept that could revolutionize personal healthcare. Imagine wearing a device equipped with sensors utilizing carbon nanotubes that can continuously monitor hormone levels, offering real-time data to patients and healthcare providers alike. Such advancements could pave the way for personalized treatment strategies and immediate interventions as fluctuations in critical biomolecules are detected.

As the research continues, the focus remains on not only improving the sensitivity and specificity of these sensor systems but also ensuring they maintain functionality within biological environments. The materials used must withstand the complexities of biological interactions while delivering reliable measurements over time. The Materials in Health Technology group at the University of Turku aims to tackle these challenges head-on, ensuring that the next generation of biosensors are not only effective but also practical for everyday use.

In summary, the innovative breakthroughs achieved by the University of Turku highlight the role nanotechnology plays in modern healthcare. By leveraging the unique properties of carbon nanotubes and refining their applications through advanced research methods, the potential for creating highly sensitive, accurate biosensors is within reach. These advancements signify a shift toward more proficient diagnostic methods that could vastly improve the understanding of hormonal health and other critical biological metrics. The future of healthcare may well depend on these small yet powerful materials, reshaping how we monitor and respond to health issues in real-time.

By embarking on this research journey, the University of Turku is not just contributing to scientific knowledge; they are laying the groundwork for a new paradigm in healthcare technology. With carbon nanotubes at the forefront, the promise of increased accuracy and sensitivity in biosensors may soon translate into tangible benefits for patients, paving the way for a healthier future.

Subject of Research: Nanotechnology and carbon nanotubes in healthcare sensor development
Article Title: Single-chirality single-wall carbon nanotubes for electrochemical biosensing
News Publication Date: 11-Feb-2025
Web References: DOI link
References: Physical Chemistry Chemical Physics
Image Credits: Mikael Nyberg

Keywords

Nanotubes, sensors, carbon nanotubes, healthcare, biosensing, chirality, hormonal monitoring, electrochemistry, University of Turku, nanotechnology.